1. Трухан Д.И. Рациональная фармакотерапия в гастроэнтерологии. Справочник поликлинического врача. 2012; 10: 18–24. / Trukhan D.I. Ratsional'naia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
2. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 11: 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9. [in Russian]
3. Трухан Д.И., Тарасова Л.В. Лекарственная безопасность и рациональная фармакотерапия в гастроэнтерологической практике. Клин. перспективы гастроэнтерологии, гепатологии. 2013; 5: 9–16. / Trukhan D.I., Tarasova L.V. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klin. perspektivy gastroenterologii, gepatologii. 2013; 5: 9–16. [in Russian]
4. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Эксперим. и клин. гастроэнтерология. 2013; 4: 81–7. / Tarasova L.V., Trukhan D.I. Lekarstvennaia bezopasnost' v gastroenterologii. Eksperim. i klin. gastroenterologiia. 2013; 4: 81–7. [in Russian]
5. Лазебник Л. Б. Полиморбидность и старение. Новости медицины и фармации. 2007; 1 (205). URL: http://archive.today/smbi / Lazebnik L. B. Polimorbidnost' i starenie. Novosti meditsiny i farmatsii. 2007; 1 (205). URL: http://archive.today/smbi [in Russian]
6. Белялов Ф.И. Двенадцать тезисов коморбидности. Клин. медицина. 2009; 12: 69–71. Belialov F.I. Dvenadtsat' tezisov komorbidnosti. Klin. meditsina. 2009; 12: 69–71. / [in Russian]
7. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31. / Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
8. Ревматология. Национальное руководство. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2008. / Revmatologiia. Natsional'noe rukovodstvo. Pod red. E.L.Nasonova. M.: GEOTAR-Media, 2008. [in Russian]
9. Рациональная фармакотерапия ревматических заболеваний. Руководство для практикующих врачей. Под общ. ред. В.А.Насоновой, Е.Л.Насонова. М.: Литтерра, 2007. / Ratsional'naia farmakoterapiia revmaticheskikh zabolevanii. Rukovodstvo dlia praktikuiushchikh vrachei. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: Litterra, 2007. [in Russian]
10. Насонов Е.Л., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Рус. мед. журн. 2006; 25: 1769–77. / Nasonov E.L., Karateev A.E. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. Rus. med. zhurn. 2006; 25: 1769–77. [in Russian]
11. Каратеев А.Е., Насонов Е.Л. НПВП-ассоциированная патология ЖКТ: реальное состояние дел в России. Рус. мед. журн. 2006; 15: 1073–8. / Karateev A.E., Nasonov E.L. NPVP-assotsiirovannaia patologiia ZhKT: real'noe sostoianie del v Rossii. Rus. med. zhurn. 2006; 15: 1073–8. [in Russian]
12. Трухан Д.И., Викторова И.А. Внутренние болезни. Кардиология. Ревматология. М.: Медицинское информационное агентство, 2013. / Trukhan D.I., Viktorova I.A. Vnutrennie bolezni. Kardiologiia. Revmatologiia. M.: Meditsinskoe informatsionnoe agentstvo, 2013. [in Russian]
13. Трухан Д.И., Филимонов С.Н., Викторова И.А. Клиника, диагностика и лечение основных ревматических болезней. СПб.: СпецЛит, 2014. / Trukhan D.I., Filimonov S.N., Viktorova I.A. Klinika, diagnostika i lechenie osnovnykh revmaticheskikh boleznei. SPb.: SpetsLit, 2014. [in Russian]
14. Лапина Т.Л. Гастропатия, индуцированная нестероидными противовоспалительными препаратами: пути решения проблемы. Рус. мед. журн. 2009; 2: 54–7. / Lapina T.L. Gastropatiia, indutsirovannaia nesteroidnymi protivovospalitel'nymi preparatami: puti resheniia problemy. Rus. med. zhurn. 2009; 2: 54–7. [in Russian]
15. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 9 (1): 4–23. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii “Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike”. Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
16. Рациональное использование нестероидных противовоспалительных препаратов. Междисциплинарный консенсус экспертов (основные положения) по результатам совещания группы экспертов 01.04.2017 г., г. Москва. Терапия. 2017; 4 (14): 114–9. / Ratsional'noe ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. Mezhdistsiplinarnyi konsensus ekspertov (osnovnye polozheniia) po rezul'tatam soveshchaniia gruppy ekspertov 01.04.2017 g., g. Moskva. Terapiia. 2017; 4 (14): 114–9. [in Russian]
17. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6: 125–31.
18. Roth SH. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy. Drugs 2012; 72 (7): 873–9.
19. Трухан Д.И. Выбор нестероидного противовоспалительного препарата с позиций профилактики НПВП-гастропатии и лекарственной безопасности. Consilium Medicum. 2014; 16 (8): 14–9. / Trukhan D.I. Choice NSAIDs from positions NSAID-gastropathy prevention and drug safety. Consilium Medicum. 2014; 16 (8): 14–9. [in Russian]
20. Трухан Д.И. Нестероидные противовоспалительные препараты сквозь призму коморбидности и лекарственной безопасности: в фокусе – амтолметин гуацил. Consilium Medicum. 2015; 17 (2): 27–33. / Trukhan D.I. Nonsteroidal anti-inflammatory drugs through the prism comorbidity and drug safety: in focus amtolmetin guatsil. Consilium Medicum. 2015; 17 (2): 27–33. [in Russian]
21. Brown TJ, Hooper L, Elliott RA et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006; 10 (38): 1–183.
22. Пасечников В.Д. Механизмы защиты слизистой оболочки желудка и NO-высвобождающие нестероидные противовоспалительные препараты. Consilium Medicum. 2013; 9: 76–80. / Pasechnikov V.D. Mekhanizmy zashchity slizistoi obolochki zheludka i NO-vysvobozhdaiushchie nesteroidnye protivovospalitel'nye preparaty. Consilium Medicum. 2013; 15 (9): 76–80. [in Russian]
23. Якоб О.В. Есть ли возможность снизить риск развития НПВП-гастропатии? Фарматека. 2013; 6: 16–21. / Iakob O.V. Est' li vozmozhnost' snizit' risk razvitiia NPVP-gastropatii? Farmateka. 2013; 6: 16–21. [in Russian]
24. Маев И.В., Лебедева Е.Г. Возможности ингибиторов протонной помпы в терапии гастропатии, индуцированной приемом нестероидных противовоспалительных препаратов, у лиц пожилого возраста. Гастроэнтерология (Прил. к журн. Consilium Medicum). 2011; 1: 16–21. / Maev I.V., Lebedeva E.G. Vozmozhnosti ingibitorov protonnoi pompy v terapii gastropatii, indutsirovannoi priemom nesteroidnykh protivovospalitel'nykh preparatov, u lits pozhilogo vozrasta. Gastroenterology (Suppl. Consilium Medicum). 2011; 1: 16–21. [in Russian]
25. Трухан Д.И., Викторова И.А. Внутренние болезни: Гастроэнтерология. СПб.: СпецЛит, 2013. / Trukhan D.I., Viktorova I.A. Vnutrennie bolezni: Gastroenterologiia. SPb.: SpetsLit, 2013. [in Russian]
26. Трухан Д.И., Тарасова Л.В., Филимонов С.Н., Викторова И.А. Болезни пищевода, желудка и двенадцатиперстной кишки. Клиника, диагностика и лечение. СПб.: СпецЛит, 2014. / Trukhan D.I., Tarasova L.V., Filimonov S.N., Viktorova I.A. Bolezni pishchevoda, zheludka i dvenadtsatiperstnoi kishki. Klinika, diagnostika i lechenie. SPb.: SpetsLit, 2014. [in Russian]
27. Вялов С.С. Противовоспалительная терапия и гастротоксичность: реальные возможности профилактики. Рус. мед. журн. 2014; 22. URL: http://rmj.ru/articles_9750.htm / Vialov S.S. Protivovospalitel'naia terapiia i gastrotoksichnost': real'nye vozmozhnosti profilaktiki. Rus. med. zhurn. 2014; 22. URL: http://rmj.ru/articles_9750.htm [in Russian]
28. Трухан Д.И., Филимонов С.Н. Заболевания кишечника: клиника, диагностика и лечение. Новокузнецк: Полиграфист, 2017. / Trukhan D.I., Filimonov S.N. Zabolevaniia kishechnika: klinika, diagnostika i lechenie. Novokuznetsk: Poligrafist, 2017. [in Russian]
29. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs. An Update for Clinicians. A Scientific Statement from the American Heart Association Circulation 2007; 115: 1634–42.
30. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
31. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
32. Каратеев А.Е. Что лучше для профилактики НПВП-гастропатии: коксибы или комбинация «традиционных» НПВП и гастропротектора? Рус. мед. журн. 2013; 13. URL: http://rmj.ru/articles_8770.htm / Karateev A.E. Chto luchshe dlia profilaktiki NPVP-gastropatii: koksiby ili kombinatsiia «traditsionnykh» NPVP i gastroprotektora? Rus. med. zhurn. 2013; 13. URL: http://rmj.ru/articles_8770.htm [in Russian]
33. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). URL:http://www.fda.gov/ cder/drug/advisory/ COX2.htm
34. Трухан Д.И., Тарасова Л.В. Рациональная фармакотерапия и лекарственная безопасность в кардиологии. Справочник поликлинического врача. 2013; 5: 21–6. / Trukhan D.I., Tarasova L.V. Ratsional'naia farmakoterapiia i lekarstvennaia bezopasnost' v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6. [in Russian]
35. Chan FK. The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment. Am J Gastroenterol 2008; 103 (1): 221–7.
36. Трухан Д.И., Тарасова Л.В., Акимова М.А. Выбор анальгетика на этапе оказания первичной медико-санитарной помощи: в фокусе внимания – кеторолак. Consilium Medicum. 2014; 2: 84–9. / Trukhan D.I., Tarasova L.V., Akimova M.A. Vybor anal'getika na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi: v fokuse vnimaniia – ketorolak. Consilium Medicum. 2014; 2: 84–9. [in Russian]
37. Трухан Д.И., Деговцов Е.Н. Выбор анальгетика для купирования болевого синдрома при костно-мышечных повреждениях (травмы, растяжения связок и вывихи суставов) и воспалительных изменениях (тендиниты, бурситы) на этапе оказания первичной медико-санитарной помощи. Хирургия (Прил. к журн. Consilium Medicum). 2016; 1: 13–7. / Trukhan D.I., Degovtsov E.N. Choice analgesics for the relief of painin bone, muscle damage (injuries, sprains and dislocations of joints) and inflammatory changes (tendinitis, bursitis) during the provision of primary health care. Surgery (Suppl. Consilium Medicum). 2016; 1: 13–7. [in Russian]
38. Трухан Д.И., Багишева Н.В. На приеме пациент с болью в грудной клетке: в фокусе – заболевания костно-мышечно-суставной системы. Справочник врача общей практики. 2016; 2: 10–7. / Trukhan D.I., Bagisheva N.V. Na prieme patsient s bol'iu v grudnoi kletke: v fokuse – zabolevaniia kostno-myshechno-sustavnoi sistemy. Spravochnik vracha obshchei praktiki. 2016; 2: 10–7. [in Russian]
39. Насонова В.А. Ацеклофенак (аэртал) в ревматологической практике. Терапевт. архив. 2005; 5: 87–90. / Nasonova V.A. Atseklofenak (aertal) v revmatologicheskoi praktike. Terapevt. arkhiv. 2005; 5: 87–90. [in Russian]
40. Каратеев А.Е. Ацеклофенак в ревматологии: «золотая середина». Соврем. ревматология. 2013; 2: 88–94. / Karateev A.E. Atseklofenak v revmatologii: “zolotaia seredina”. Sovrem. revmatologiia. 2013; 2: 88–94. [in Russian]
41. Legrand E. Aceclofenac in the management of inflammatory pain. Exp Opion Pharmacother 2004; 5 (6): 1347–57.
42. Reginster J, Paul I, Henrotin Y. What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies? Rev Med Liege 2001; 56 (7): 484–8.
43. Saraf S. Aceclofenac: a potent nonsteroidal anti-inflammatory drug in latest reviews. Latest Rev 2006; 4 (3): 119–24.
44. Аэртал® (Airtal®): инструкция по применению. URL: https://www.vidal.ru/drugs/airtal__2535 / Aertal® (Airtal®): instruktsiia po primeneniiu. URL: https://www.vidal.ru/drugs/airtal__2535 [in Russian]
45. Hinz B, Rau T, Auge D et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74: 222–35.
46. Dingle J. The effects of NSAID on the matrix of human articular cartilages. Z Rheum 1999; 58 (3): 125–9.
47. Blot L, Marcelis A, Devogelaer J, Manicourt D. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000; 131 (7): 1413–21.
48. Moon YW, Kang SB, Kim TK, Lee MC. Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. Knee Surg Relat Res 2014; 26 (1): 33–42.
49. Batlle-Gualda E, Roman Ivorra J, Martin-Mola E et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6week randomized controlled trial. Osteoarthr Cartil 2007; 15 (8): 900–8.
50. Ward D, Veys E, Bowdler J, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheum 1995; 14 (6): 656–62.
51. Pareek A, Chandurkar N. Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin 2013; 29 (7): 849–59.
52. Kornasoff D, Frerick H, Bowdler J, Montull E. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheum 1997; 16 (1): 32–8.
53. Perez Busquier M, Calero E, Rodriguez M et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheum 1997; 16 (2): 154–9.
54. Accardo S, Seriolo B, Tirri G et al. Long term safety profile of aceclofenac in the treatment of articular pain. Eur J Rheumatol Inflamm 1996; 16: 29–35.
55. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol 2017; 4 (1): 11–8.
56. Раскина Т.А. Ацеклофенак: терапевтическая эффективность при остеоартрозе. Соврем. ревматология. 2010; 4: 51–4. / Raskina T.A. Atseklofenak: terapevticheskaia effektivnost' pri osteoartroze. Sovrem. revmatologiia. 2010; 4: 51–4. [in Russian]
57. Замятина Е.А., Багирова Г.Г. Применение мелоксикама (мовалиса) и ацеклофенака (аэртала) у лиц пожилого возраста с остеоартрозом. Известия высших учебных заведений. Поволжский регион. Мед. науки. 2012; 1: 40–6. / Zamiatina E.A., Bagirova G.G. Primenenie meloksikama (movalisa) i atseklofenaka (aertala) u lits pozhilogo vozrasta s osteoartrozom. Izvestiia vysshikh uchebnykh zavedenii. Povolzhskii region. Med. nauki. 2012; 1: 40–6. [in Russian]
58. Мартусевич Н.А., Алешкевич А.И., Сидоренко В.А., Сергейчик О.В. Сравнительная оценка эффективности и безопасности применения лекарственных средств ацеклофенак (Airtal®) и диклофенак (Diclopol®) у пациентов с гонартрозом I–II рентгенологической стадии. Международные обзоры: клиническая практика и здоровье. 2013; 4: 69–78. / Martusevich N.A., Aleshkevich A.I., Sidorenko V.A., Sergeichik O.V. Sravnitel'naia otsenka effektivnosti i bezopasnosti primeneniia lekarstvennykh sredstv atseklofenak (Airtal®) i diklofenak (Diclopol®) u patsientov s gonartrozom I–II rentgenologicheskoi stadii. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2013; 4: 69–78. [in Russian]
59. Шарапова Е.П., Кашеварова Н.Г., Аникин С.Г. и др. Применение ацеклофенака при остеоартрозе. Клин. фармакология и терапия. 2014; 2: 78–82. / Sharapova E.P., Kashevarova N.G., Anikin S.G. i dr. Primenenie atseklofenaka pri osteoartroze. Klin. farmakologiia i terapiia. 2014; 2: 78–82. [in Russian]
60. Загородний Н.В., Ивашкин А.Н., Закирова А.Р., Скипенко Т.О. Применение ацеклофенака (Аэртал) на ранних стадиях гонартроза. Consilium Medicum. 2016; 18 (8): 42–5. / Zagorodniy N.V., Ivashkin A.N., Zakirova A.R., Skipenko T.О. Use of aceclofenac (Aertal) in early stages arthrosis of the knee joint. Consilium Medicum. 2016; 18 (8): 42–5. [in Russian]
61. Цурко В.В., Иванова Т.Б. Ацеклофенак (аэртал): данные экспериментальных и клинических исследований при суставном синдроме. Клин. геронтология. 2009; 2: 50–4. / Tsurko V.V., Ivanova T.B. Atseklofenak (aertal): dannye eksperimental'nykh i klinicheskikh issledovanii pri sustavnom sindrome. Klin. gerontologiia. 2009; 2: 50–4. [in Russian]
62. Балабанова Р.М. Аэртал – анальгетический и противовоспалительный эффект при ревматических заболеваниях. РМЖ. 2011; 25: 1544–5. / Balabanova R.M. Aertal – anal'geticheskii i protivovospalitel'nyi effekt pri revmaticheskikh zabolevaniiakh. RMZh. 2011; 25: 1544–5. [in Russian]
63. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61 (9): 1351–78.
64. Lemmel E, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin 2002; 18 (3): 146–53.
65. Леммел У.М., Лееп Б., Баст Дж., Асландис С. Удовлетворенность пациентов и врачей препаратом ацеклофенак: результаты Европейского обсервационного когортного исследования (опыт применения ацеклофенака при болях воспалительного происхождения в повседневной практике). РМЖ. 2003; 7: 410–5. / Lemmel U.M., Leep B., Bast Dzh., Aslandis S. Udovletvorennost' patsientov i vrachei preparatom atseklofenak: rezul'taty Evropeiskogo observatsionnogo kogortnogo issledovaniia (opyt primeneniia atseklofenaka pri boliakh vospalitel'nogo proiskhozhdeniia v povsednevnoi praktike). RMZh. 2003; 7: 410–5. [in Russian]
66. Лила А.М. Применение аэртала (ацеклофенака) в клинической практике. РМЖ. 2009; 4: 291–4. / Lila A.M. Primenenie aertala (atseklofenaka) v klinicheskoi praktike. RMZh. 2009; 4: 291–4. [in Russian]
67. Pasero G, Marcolongo R, Serni U et al. A multi-center, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac. In the treatment of rheumatoid arthritis. Curr Med Res Opin 1995; 13: 305–15.
68. Martin-Mola E, Gijon-Banos J, Ansoleaga J. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Rheum Int 1995; 15 (3): 111–6.
69. Pasero G, Ruju G, Macolongo R et al. Aceclofenac versus naproхen in the treatment of ankylosing spondylitis: a double-blend, controlled study. Curr Nher Res 1994; 55: 833–42.
70. Batlle-Gualda E, Figueroa M, Ivorra J, Raber A. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996; 23 (7): 1200–6.
71. Villa-Alcazar LF, de Buergo M, Rico Lensa H, Montull Fruitos E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996; 23 (7): 1194–9.
72. Brogden RN, Wiseman LR. Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 1996; 52 (1): 113–24.
73. Кундер Е.В. Лечение псориатического артрита. Международные обзоры: клиническая практика и здоровье. 2013; 6 (6): 105–29. / Kunder E.V. Lechenie psoriaticheskogo artrita. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2013; 6 (6): 105–29. [in Russian]
74. Schattenkirchner M, Milachowski K. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol 2003; 22 (2): 127–35.
75. Pareek A, Chandurkar N, Chandanwale AS et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009; 18 (12): 1836–42.
76. Кукушкин М.Л. Аэртал в комплексной терапии неспецифической боли внизу спины. Неврол. журн. 2010; 5: 57–61. / Kukushkin M.L. Aertal v kompleksnoi terapii nespetsificheskoi boli vnizu spiny. Nevrol. zhurn. 2010; 5: 57–61. [in Russian]
77. Цурко В.В., Егоров И.В., Красносельский М.Я. и др. Анатомо-функциональные особенности позвоночника у пожилых: роль ацеклофенака в купировании дорсопатии. Consilium Medicum. 2010; 12 (9): 5–9. / Tsurko V.V., Egorov I.V., Krasnosel'skii M.Ia. i dr. Anatomo-funktsional'nye osobennosti pozvonochnika u pozhilykh: rol' atseklofenaka v kupirovanii dorsopatii. Consilium Medicum. 2010; 12 (9): 5–9. [in Russian]
78. Корсакова Ю.Л. Применение ацеклофенака (аэртала) при боли в спине. Соврем. ревматология. 2011; 2: 55–61. / Korsakova Iu.L. Primenenie atseklofenaka (aertala) pri boli v spine. Sovrem. revmatologiia. 2011; 2: 55–61. [in Russian]
79. Парфенов В.А., Герасимова О.Н. Использование ацеклофенака (аэртал) при неспецифической боли в спине и других заболеваниях. Неврология, нейропсихиатрия, психосоматика. 2011; 4: 90–4. / Parfenov V.A., Gerasimova O.N. Ispol'zovanie atseklofenaka (aertal) pri nespetsificheskoi boli v spine i drugikh zabolevaniiakh. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2011; 4: 90–4. [in Russian]
80. Исаенко С.С., Пешкова С.Ю. Опыт применения ацеклофенака в комплексной терапии острого болевого синдрома у пациентов с болью в нижней части спины. Соврем. проблемы ревматологии. 2014; 6 (6): 53–6. / Isaenko S.S., Peshkova S.Iu. Opyt primeneniia atseklofenaka v kompleksnoi terapii ostrogo bolevogo sindroma u patsientov s bol'iu v nizhnei chasti spiny. Sovrem. problemy revmatologii. 2014; 6 (6): 53–6. [in Russian]
81. Космачев В.Е., Шамова Т.М. Лечение вертеброгенных синдромов в амбулаторной практике. Международные обзоры: клиническая практика и здоровье. 2014; 1 (7): 153–9. / Kosmachev V.E., Shamova T.M. Lechenie vertebrogennykh sindromov v ambulatornoi praktike. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 1 (7): 153–9. [in Russian]
82. Погожева Е.Ю., Амирджанова В.Н., Старкова А.С. Оценка эффективности анальгетической терапии и функционального состояния пациентов с неспецифической болью в спине в амбулаторной практике. Неврология и ревматология (Прил. к журн. Consilium Medicum). 2014; 1: 13–6. / Pogozheva E.Iu., Amirdzhanova V.N., Starkova A.S. Otsenka effektivnosti anal'geticheskoi terapii i funktsional'nogo sostoianiia patsientov s nespetsificheskoi bol'iu v spine v ambulatornoi praktike. Neurology and Rheumatology (Suppl. Consilium Medicum). 2014; 1: 13–6. [in Russian]
83. Yang JH, Suk KS1, Lee BH. Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. Yonsei Med J 2017; 58 (3): 637–43.
84. Grau M, Guasch J, Montero J et al. Pharmacology of the potent new nonsteroidal anti-inflammatory agent aceclofenac. Arzneimittelforschung 1991; 41 (12): 1265–76.
85. Sharma G, Singh J, Anand D et al. Aceclofenac: Species-Dependent Metabolism and Newer Paradigm Shift from Oral to Non-oral Delivery. Curr Top Med Chem 2017; 17 (2): 107–19.
86. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46.
87. Huskisson E, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Europ. J Rheumatol Inflamm 2007; 7 (1): 1–7.
88. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27: 411–20.
89. Lanas A, Garsia-Rodriguez L, Arroyo M et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-steroidal non-aspirin NSAID, aspirin, and combinations. Gut 2006; 55 (12): 1731–8.
90. Melero LMJ, Burillo TJM, Zaragoza M. Comparative incidence of upper gastrointestinal bleeding associated with individual nonsteroidal anti-inflammatory drugs. Rev Esp Enferm Dig 2002; 94: 7–18.
91. Raber A, Heras J, Costa J et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Manag 2007; 3: 225–30.
92. Peris F, Bird HA, Serni U et al. Treatment compliance and safety of aceclofenac versus NSAIDs in patients with common arthritis disorders: a meta-analysis. Eur Rheumatol Inflamm 1996; 16: 37–45.
93. Каратеев А.Е., Денисов Л.Н., Маркелова Е.И. и др. Результаты клинического исследования АЭРОПЛАН (анализ эффективности и риска осложнений при лечении артрита ацеклофенаком и нимесулидом). Consilium Medicum. 2013; 15 (2): 52–7. / Karateev A.E., Denisov L.N., Markelova E.I. i dr. Rezul'taty klinicheskogo issledovaniia AEROPLAN (analiz effektivnosti i riska oslozhnenii pri lechenii artrita atseklofenakom i nimesulidom). Consilium Medicum. 2013; 15 (2): 52–7. [in Russian]
94. Силивончик Н.Н. Ацеклофенак: профиль гастроинтестинальной безопасности. Международные обзоры: клиническая практика и здоровье. 2014; 2 (8): 95–104. / Silivonchik N.N. Atseklofenak: profil' gastrointestinal'noi bezopasnosti. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 2 (8): 95–104. [in Russian]
95. Marsicano LJ, Ocampo ME. Hepatic tolerance of aceclofenac. GEN 1994; 48 (4): 250–5.
96. Helin-Salmivaara A, Virtanen A, Veslainen R et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland Eur Heart 2006; 27: 1657–63.
97. Журавлева М.В. Актуальные вопросы применения нестероидных противовоспалительных средств: возможности применения ацеклофенака. Фарматека. 2011; 9: 33–8. / Zhuravleva M.V. Aktual'nye voprosy primeneniia nesteroidnykh protivovospalitel'nykh sredstv: vozmozhnosti primeneniia atseklofenaka. Farmateka. 2011; 9: 33–8. [in Russian]
98. Василевский И.В. Клинико-фармакологическая гетерогенность нестероидных противовоспалительных лекарственных средств: фокус на ацеклофенак. Международные обзоры: клиническая практика и здоровье. 2015; 2 (14): 61–78. / Vasilevskii I.V. Kliniko-farmakologicheskaia geterogennost' nesteroidnykh protivovospalitel'nykh lekarstvennykh sredstv: fokus na atseklofenak. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2015; 2 (14): 61–78. [in Russian]
99. Мякотных В.С., Торгашов М.Н. Стресс-индуцированные болевые синдромы и возможности их лечения с применением новой формы ацеклофенака. Клин. фармакология и терапия. 2015; 24 (2): 26–30. / Miakotnykh V.S., Torgashov M.N. Stress-indutsirovannye bolevye sindromy i vozmozhnosti ikh lecheniia s primeneniem novoi formy atseklofenaka. Klin. farmakologiia i terapiia. 2015; 24 (2): 26–30. [in Russian]
100. Войченко Н.В., Сущеня Е.А., Волотовская А.В. Применение фотомагнитотерапии и ультрафонофореза 1,5% крема «аэртал» при остеоартрозе. Международные обзоры: клиническая практика и здоровье. 2016; 5–6 (23): 35–40. / Voichenko N.V., Sushchenia E.A., Volotovskaia A.V. Primenenie fotomagnitoterapii i ul'trafonoforeza 1,5% krema “aertal” pri osteoartroze. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2016; 5–6 (23): 35–40. [in Russian]

________________________________________________

1. Trukhan D.I. Ratsional'naia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
2. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9. [in Russian]
3. Trukhan D.I., Tarasova L.V. Lekarstvennaia bezopasnost' i ratsional'naia farmakoterapiia v gastroenterologicheskoi praktike. Klin. perspektivy gastroenterologii, gepatologii. 2013; 5: 9–16. [in Russian]
4. Tarasova L.V., Trukhan D.I. Lekarstvennaia bezopasnost' v gastroenterologii. Eksperim. i klin. gastroenterologiia. 2013; 4: 81–7. [in Russian]
5. Lazebnik L. B. Polimorbidnost' i starenie. Novosti meditsiny i farmatsii. 2007; 1 (205). URL: http://archive.today/smbi [in Russian]
6. Belialov F.I. Dvenadtsat' tezisov komorbidnosti. Klin. meditsina. 2009; 12: 69–71. / [in Russian]
7. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
8. Revmatologiia. Natsional'noe rukovodstvo. Pod red. E.L.Nasonova. M.: GEOTAR-Media, 2008. [in Russian]
9. Ratsional'naia farmakoterapiia revmaticheskikh zabolevanii. Rukovodstvo dlia praktikuiushchikh vrachei. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: Litterra, 2007. [in Russian]
10. Nasonov E.L., Karateev A.E. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. Rus. med. zhurn. 2006; 25: 1769–77. [in Russian]
11. Karateev A.E., Nasonov E.L. NPVP-assotsiirovannaia patologiia ZhKT: real'noe sostoianie del v Rossii. Rus. med. zhurn. 2006; 15: 1073–8. [in Russian]
12. Trukhan D.I., Viktorova I.A. Vnutrennie bolezni. Kardiologiia. Revmatologiia. M.: Meditsinskoe informatsionnoe agentstvo, 2013. [in Russian]
13. Trukhan D.I., Filimonov S.N., Viktorova I.A. Klinika, diagnostika i lechenie osnovnykh revmaticheskikh boleznei. SPb.: SpetsLit, 2014. [in Russian]
14. Lapina T.L. Gastropatiia, indutsirovannaia nesteroidnymi protivovospalitel'nymi preparatami: puti resheniia problemy. Rus. med. zhurn. 2009; 2: 54–7. [in Russian]
15. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii “Ratsional'noe primenenie nesteroidnykh protivovospalitel'nykh preparatov (NPVP) v klinicheskoi praktike”. Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
16. Ratsional'noe ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. Mezhdistsiplinarnyi konsensus ekspertov (osnovnye polozheniia) po rezul'tatam soveshchaniia gruppy ekspertov 01.04.2017 g., g. Moskva. Terapiia. 2017; 4 (14): 114–9. [in Russian]
17. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6: 125–31.
18. Roth SH. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy. Drugs 2012; 72 (7): 873–9.
19. Trukhan D.I. Choice NSAIDs from positions NSAID-gastropathy prevention and drug safety. Consilium Medicum. 2014; 16 (8): 14–9. [in Russian]
20. Trukhan D.I. Nonsteroidal anti-inflammatory drugs through the prism comorbidity and drug safety: in focus amtolmetin guatsil. Consilium Medicum. 2015; 17 (2): 27–33. [in Russian]
21. Brown TJ, Hooper L, Elliott RA et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Health Technol Assess 2006; 10 (38): 1–183.
22. Pasechnikov V.D. Mekhanizmy zashchity slizistoi obolochki zheludka i NO-vysvobozhdaiushchie nesteroidnye protivovospalitel'nye preparaty. Consilium Medicum. 2013; 15 (9): 76–80. [in Russian]
23. Iakob O.V. Est' li vozmozhnost' snizit' risk razvitiia NPVP-gastropatii? Farmateka. 2013; 6: 16–21. [in Russian]
24. Maev I.V., Lebedeva E.G. Vozmozhnosti ingibitorov protonnoi pompy v terapii gastropatii, indutsirovannoi priemom nesteroidnykh protivovospalitel'nykh preparatov, u lits pozhilogo vozrasta. Gastroenterology (Suppl. Consilium Medicum). 2011; 1: 16–21. [in Russian]
25. Trukhan D.I., Viktorova I.A. Vnutrennie bolezni: Gastroenterologiia. SPb.: SpetsLit, 2013. [in Russian]
26. Trukhan D.I., Tarasova L.V., Filimonov S.N., Viktorova I.A. Bolezni pishchevoda, zheludka i dvenadtsatiperstnoi kishki. Klinika, diagnostika i lechenie. SPb.: SpetsLit, 2014. [in Russian]
27. Vialov S.S. Protivovospalitel'naia terapiia i gastrotoksichnost': real'nye vozmozhnosti profilaktiki. Rus. med. zhurn. 2014; 22. URL: http://rmj.ru/articles_9750.htm [in Russian]
28. Trukhan D.I., Filimonov S.N. Zabolevaniia kishechnika: klinika, diagnostika i lechenie. Novokuznetsk: Poligrafist, 2017. [in Russian]
29. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs. An Update for Clinicians. A Scientific Statement from the American Heart Association Circulation 2007; 115: 1634–42.
30. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
31. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
32. Karateev A.E. Chto luchshe dlia profilaktiki NPVP-gastropatii: koksiby ili kombinatsiia «traditsionnykh» NPVP i gastroprotektora? Rus. med. zhurn. 2013; 13. URL: http://rmj.ru/articles_8770.htm [in Russian]
33. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). URL:http://www.fda.gov/ cder/drug/advisory/ COX2.htm
34. Trukhan D.I., Tarasova L.V. Ratsional'naia farmakoterapiia i lekarstvennaia bezopasnost' v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6. [in Russian]
35. Chan FK. The David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environment. Am J Gastroenterol 2008; 103 (1): 221–7.
36. Trukhan D.I., Tarasova L.V., Akimova M.A. Vybor anal'getika na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi: v fokuse vnimaniia – ketorolak. Consilium Medicum. 2014; 2: 84–9. [in Russian]
37. Trukhan D.I., Degovtsov E.N. Choice analgesics for the relief of painin bone, muscle damage (injuries, sprains and dislocations of joints) and inflammatory changes (tendinitis, bursitis) during the provision of primary health care. Surgery (Suppl. Consilium Medicum). 2016; 1: 13–7. [in Russian]
38. Trukhan D.I., Bagisheva N.V. Na prieme patsient s bol'iu v grudnoi kletke: v fokuse – zabolevaniia kostno-myshechno-sustavnoi sistemy. Spravochnik vracha obshchei praktiki. 2016; 2: 10–7. [in Russian]
39. Nasonova V.A. Atseklofenak (aertal) v revmatologicheskoi praktike. Terapevt. arkhiv. 2005; 5: 87–90. [in Russian]
40. Karateev A.E. Atseklofenak v revmatologii: “zolotaia seredina”. Sovrem. revmatologiia. 2013; 2: 88–94. [in Russian]
41. Legrand E. Aceclofenac in the management of inflammatory pain. Exp Opion Pharmacother 2004; 5 (6): 1347–57.
42. Reginster J, Paul I, Henrotin Y. What is the role of aceclofenac in the therapeutic arsenal against chronic osteoarthritis pathologies? Rev Med Liege 2001; 56 (7): 484–8.
43. Saraf S. Aceclofenac: a potent nonsteroidal anti-inflammatory drug in latest reviews. Latest Rev 2006; 4 (3): 119–24.
44. Aertal® (Airtal®): instruktsiia po primeneniiu. URL: https://www.vidal.ru/drugs/airtal__2535 [in Russian]
45. Hinz B, Rau T, Auge D et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74: 222–35.
46. Dingle J. The effects of NSAID on the matrix of human articular cartilages. Z Rheum 1999; 58 (3): 125–9.
47. Blot L, Marcelis A, Devogelaer J, Manicourt D. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br J Pharmacol 2000; 131 (7): 1413–21.
48. Moon YW, Kang SB, Kim TK, Lee MC. Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study. Knee Surg Relat Res 2014; 26 (1): 33–42.
49. Batlle-Gualda E, Roman Ivorra J, Martin-Mola E et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6week randomized controlled trial. Osteoarthr Cartil 2007; 15 (8): 900–8.
50. Ward D, Veys E, Bowdler J, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheum 1995; 14 (6): 656–62.
51. Pareek A, Chandurkar N. Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double-blind study in patients with knee osteoarthritis. Curr Med Res Opin 2013; 29 (7): 849–59.
52. Kornasoff D, Frerick H, Bowdler J, Montull E. Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin Rheum 1997; 16 (1): 32–8.
53. Perez Busquier M, Calero E, Rodriguez M et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheum 1997; 16 (2): 154–9.
54. Accardo S, Seriolo B, Tirri G et al. Long term safety profile of aceclofenac in the treatment of articular pain. Eur J Rheumatol Inflamm 1996; 16: 29–35.
55. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol 2017; 4 (1): 11–8.
56. Raskina T.A. Atseklofenak: terapevticheskaia effektivnost' pri osteoartroze. Sovrem. revmatologiia. 2010; 4: 51–4. [in Russian]
57. Zamiatina E.A., Bagirova G.G. Primenenie meloksikama (movalisa) i atseklofenaka (aertala) u lits pozhilogo vozrasta s osteoartrozom. Izvestiia vysshikh uchebnykh zavedenii. Povolzhskii region. Med. nauki. 2012; 1: 40–6. [in Russian]
58. Martusevich N.A., Aleshkevich A.I., Sidorenko V.A., Sergeichik O.V. Sravnitel'naia otsenka effektivnosti i bezopasnosti primeneniia lekarstvennykh sredstv atseklofenak (Airtal®) i diklofenak (Diclopol®) u patsientov s gonartrozom I–II rentgenologicheskoi stadii. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2013; 4: 69–78. [in Russian]
59. Sharapova E.P., Kashevarova N.G., Anikin S.G. i dr. Primenenie atseklofenaka pri osteoartroze. Klin. farmakologiia i terapiia. 2014; 2: 78–82. [in Russian]
60. Zagorodniy N.V., Ivashkin A.N., Zakirova A.R., Skipenko T.О. Use of aceclofenac (Aertal) in early stages arthrosis of the knee joint. Consilium Medicum. 2016; 18 (8): 42–5. [in Russian]
61. Tsurko V.V., Ivanova T.B. Atseklofenak (aertal): dannye eksperimental'nykh i klinicheskikh issledovanii pri sustavnom sindrome. Klin. gerontologiia. 2009; 2: 50–4. [in Russian]
62. Balabanova R.M. Aertal – anal'geticheskii i protivovospalitel'nyi effekt pri revmaticheskikh zabolevaniiakh. RMZh. 2011; 25: 1544–5. [in Russian]
63. Dooley M, Spencer C, Dunn C. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61 (9): 1351–78.
64. Lemmel E, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin 2002; 18 (3): 146–53.
65. Lemmel U.M., Leep B., Bast Dzh., Aslandis S. Udovletvorennost' patsientov i vrachei preparatom atseklofenak: rezul'taty Evropeiskogo observatsionnogo kogortnogo issledovaniia (opyt primeneniia atseklofenaka pri boliakh vospalitel'nogo proiskhozhdeniia v povsednevnoi praktike). RMZh. 2003; 7: 410–5. [in Russian]
66. Lila A.M. Primenenie aertala (atseklofenaka) v klinicheskoi praktike. RMZh. 2009; 4: 291–4. [in Russian]
67. Pasero G, Marcolongo R, Serni U et al. A multi-center, double-blind comparative study of the efficacy and safety of aceclofenac and diclofenac. In the treatment of rheumatoid arthritis. Curr Med Res Opin 1995; 13: 305–15.
68. Martin-Mola E, Gijon-Banos J, Ansoleaga J. Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthritis. Rheum Int 1995; 15 (3): 111–6.
69. Pasero G, Ruju G, Macolongo R et al. Aceclofenac versus naproхen in the treatment of ankylosing spondylitis: a double-blend, controlled study. Curr Nher Res 1994; 55: 833–42.
70. Batlle-Gualda E, Figueroa M, Ivorra J, Raber A. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 1996; 23 (7): 1200–6.
71. Villa-Alcazar LF, de Buergo M, Rico Lensa H, Montull Fruitos E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996; 23 (7): 1194–9.
72. Brogden RN, Wiseman LR. Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management. Drugs 1996; 52 (1): 113–24.
73. Kunder E.V. Lechenie psoriaticheskogo artrita. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2013; 6 (6): 105–29. [in Russian]
74. Schattenkirchner M, Milachowski K. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol 2003; 22 (2): 127–35.
75. Pareek A, Chandurkar N, Chandanwale AS et al. Aceclofenac-tizanidine in the treatment of acute low back pain: a double-blind, double-dummy, randomized, multicentric, comparative study against aceclofenac alone. Eur Spine J 2009; 18 (12): 1836–42.
76. Kukushkin M.L. Aertal v kompleksnoi terapii nespetsificheskoi boli vnizu spiny. Nevrol. zhurn. 2010; 5: 57–61. [in Russian]
77. Tsurko V.V., Egorov I.V., Krasnosel'skii M.Ia. i dr. Anatomo-funktsional'nye osobennosti pozvonochnika u pozhilykh: rol' atseklofenaka v kupirovanii dorsopatii. Consilium Medicum. 2010; 12 (9): 5–9. [in Russian]
78. Korsakova Iu.L. Primenenie atseklofenaka (aertala) pri boli v spine. Sovrem. revmatologiia. 2011; 2: 55–61. [in Russian]
79. Parfenov V.A., Gerasimova O.N. Ispol'zovanie atseklofenaka (aertal) pri nespetsificheskoi boli v spine i drugikh zabolevaniiakh. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2011; 4: 90–4. [in Russian]
80. Isaenko S.S., Peshkova S.Iu. Opyt primeneniia atseklofenaka v kompleksnoi terapii ostrogo bolevogo sindroma u patsientov s bol'iu v nizhnei chasti spiny. Sovrem. problemy revmatologii. 2014; 6 (6): 53–6. [in Russian]
81. Kosmachev V.E., Shamova T.M. Lechenie vertebrogennykh sindromov v ambulatornoi praktike. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 1 (7): 153–9. [in Russian]
82. Pogozheva E.Iu., Amirdzhanova V.N., Starkova A.S. Otsenka effektivnosti anal'geticheskoi terapii i funktsional'nogo sostoianiia patsientov s nespetsificheskoi bol'iu v spine v ambulatornoi praktike. Neurology and Rheumatology (Suppl. Consilium Medicum). 2014; 1: 13–6. [in Russian]
83. Yang JH, Suk KS1, Lee BH. Efficacy and Safety of Different Aceclofenac Treatments for Chronic Lower Back Pain: Prospective, Randomized, Single Center, Open-Label Clinical Trials. Yonsei Med J 2017; 58 (3): 637–43.
84. Grau M, Guasch J, Montero J et al. Pharmacology of the potent new nonsteroidal anti-inflammatory agent aceclofenac. Arzneimittelforschung 1991; 41 (12): 1265–76.
85. Sharma G, Singh J, Anand D et al. Aceclofenac: Species-Dependent Metabolism and Newer Paradigm Shift from Oral to Non-oral Delivery. Curr Top Med Chem 2017; 17 (2): 107–19.
86. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127–46.
87. Huskisson E, Irani M, Murray F. A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Europ. J Rheumatol Inflamm 2007; 7 (1): 1–7.
88. Laporte J, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27: 411–20.
89. Lanas A, Garsia-Rodriguez L, Arroyo M et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-steroidal non-aspirin NSAID, aspirin, and combinations. Gut 2006; 55 (12): 1731–8.
90. Melero LMJ, Burillo TJM, Zaragoza M. Comparative incidence of upper gastrointestinal bleeding associated with individual nonsteroidal anti-inflammatory drugs. Rev Esp Enferm Dig 2002; 94: 7–18.
91. Raber A, Heras J, Costa J et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther Clin Risk Manag 2007; 3: 225–30.
92. Peris F, Bird HA, Serni U et al. Treatment compliance and safety of aceclofenac versus NSAIDs in patients with common arthritis disorders: a meta-analysis. Eur Rheumatol Inflamm 1996; 16: 37–45.
93. Karateev A.E., Denisov L.N., Markelova E.I. i dr. Rezul'taty klinicheskogo issledovaniia AEROPLAN (analiz effektivnosti i riska oslozhnenii pri lechenii artrita atseklofenakom i nimesulidom). Consilium Medicum. 2013; 15 (2): 52–7. [in Russian]
94. Silivonchik N.N. Atseklofenak: profil' gastrointestinal'noi bezopasnosti. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2014; 2 (8): 95–104. [in Russian]
95. Marsicano LJ, Ocampo ME. Hepatic tolerance of aceclofenac. GEN 1994; 48 (4): 250–5.
96. Helin-Salmivaara A, Virtanen A, Veslainen R et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national case-control study from Finland Eur Heart 2006; 27: 1657–63.
97. Zhuravleva M.V. Aktual'nye voprosy primeneniia nesteroidnykh protivovospalitel'nykh sredstv: vozmozhnosti primeneniia atseklofenaka. Farmateka. 2011; 9: 33–8. [in Russian]
98. Vasilevskii I.V. Kliniko-farmakologicheskaia geterogennost' nesteroidnykh protivovospalitel'nykh lekarstvennykh sredstv: fokus na atseklofenak. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2015; 2 (14): 61–78. [in Russian]
99. Miakotnykh V.S., Torgashov M.N. Stress-indutsirovannye bolevye sindromy i vozmozhnosti ikh lecheniia s primeneniem novoi formy atseklofenaka. Klin. farmakologiia i terapiia. 2015; 24 (2): 26–30. [in Russian]
100. Voichenko N.V., Sushchenia E.A., Volotovskaia A.V. Primenenie fotomagnitoterapii i ul'trafonoforeza 1,5% krema “aertal” pri osteoartroze. Mezhdunarodnye obzory: klinicheskaia praktika i zdorov'e. 2016; 5–6 (23): 35–40. [in Russian]

Д.И.Трухан

ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
dmitry_trukhan@mail.ru

________________________________________________

D.I.Trukhan

Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, 12
dmitry_trukhan@mail.ru